

touchREVIEWS

in Oncology & Haematology

VOLUME 17 • ISSUE 2 • 2021

EDITORS-IN-CHIEF: SHAJI K KUMAR
AXEL S MERSEBURGER

New Checkpoint Inhibitors and Immunotherapies for Solid Tumours

Inderjit Mehmi, Kristopher P Wentzel and Omid Hamid

Daratumumab for Immunoglobulin Light Chain Amyloidosis

Meletios A Dimopoulos, Efsthios Kastritis and
Foteini Theodorakakou

A New Standard of Care: Pembrolizumab in Programmed Death-ligand 1 Positive, Metastatic, Triple-negative Breast Cancer

Kai CC Johnson, Robert Wesolowski and
Margaret E Gatti-Mays


www.touchONCOLOGY.com

touchREVIEWS

in Oncology & Haematology

Volume 17 • Issue 2 • 2021

Cover image: DNA strand and Cancer Cell Oncology
Research Concept 3D rendering By catalin
©stock.adobe.com



touchREVIEWS in Oncology & Haematology wishes to thank the organizations below for their assistance. This does not constitute any official endorsement.



Editorial Directors

Helen Fowler (Therapy Lead)
Gina Furnival

Commissioning Editors

Katey Gabrysch
Victoria Jones
Sophie Nickelson

Editorial Workflow

Lisa Glass
Heather Hall
Joanna Macdiarmid

Editorial Assistant

Louise Taylor

Design Manager

Julie Stevenson

Group Head Medical & Editorial

Nicola Cartridge
E: nicola.cartridge@touchmedicalmedia.com
T: +44 (0)20 7193 3186

CEO & Managing Director

Barney Kent
E: barney.kent@touchmedicalmedia.com
T: +44 (0)20 7193 3009

Head of Strategic Partnerships

Caroline Markham
E: caroline.markham@touchmedicalmedia.com
T: +44 (0)20 7193 3704

All information obtained by Touch Medical Media and each of the contributors from various sources is as current and accurate as possible. However, due to human or mechanical errors, Touch Medical Media and the contributors cannot guarantee the accuracy, adequacy or completeness of any information, and cannot be held responsible for any errors or omissions, or for the results obtained from the use thereof. Where opinion is expressed, it is that of the authors and does not necessarily coincide with the editorial views of Touch Medical Media. Statistical and financial data in this publication have been compiled on the basis of factual information and do not constitute any investment advertisement or investment advice. For the avoidance of doubt, the information contained in this publication is intended for use by licensed medical professionals. The content should not be considered medical advice, diagnosis or treatment recommendations.

© 2021 Touch Medical Media Services Limited, a private limited company registered in England and Wales at Lancashire Gate, 21 Tiviot Dale, Stockport, Cheshire, SK1 1TD with registered number 12930327. All rights reserved. eISSN: 2752-5481



www.touchmedicalmedia.com

touchREVIEWS

in Oncology & Haematology

Editors-in-Chief

Shaji K Kumar
Mayo Clinic, Rochester, MN, USA

Axel S Merseburger
Department of Urology, Campus Lübeck, University Hospital Schleswig-Holstein, Lübeck, Germany

Section Editors

Michele Baccarani
Institute of Hematology 'L and A Seragnoli', University of Bologna, Bologna, Italy

Pagona Lagiou
Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece

Marc Peeters
Oncology Department, Antwerp University Hospital; Multidisciplinary Oncology Center Antwerp, Edegem, Belgium

Maurice Pérol
Thoracic Oncology, Medical Oncology Department of Léon Bérard Cancer Center, Lyon, France

Bernardo L Rapoport
The Medical Oncology Centre of Rosebank, Johannesburg, South Africa

Bertrand Tombal
Service d'Urologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium

Editorial Board

Matti S Aapro
Multidisciplinary Oncology Institute, Genolier, Switzerland

Eleni Andreopoulou
University of Texas MD Anderson Cancer Center, Houston, TX, USA

Anne Angelillo-Scherrer
Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Bern, Switzerland

Mutlu Arat
Hematopoietic Stem Cell Transplantation Unit, Sisli Florence Nightingale Hospital, Istanbul, Turkey

Paolo A Ascierto
Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Tumor Institute 'Fondazione G Pascale', Naples, Italy

Ahmad Awada
Medical Oncology Clinic, Jules Bordet Institute, Brussels, Belgium

Wadie F Bahou
State University of New York, Stony Brook, NY, USA

Tanios Bekaii-Saab
Mayo Clinic, Phoenix, AZ, USA

P Leif Bergsagel
Mayo Clinic, Rochester, MN, USA

Erik Berntop
Malmö Haemophilia Centre; Department for Coagulation Disorders, Malmö University Hospital, Malmö, Sweden

Peter Black
Vancouver Prostate Center, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada

Hal E Broxmeyer
Indiana University School of Medicine, Indianapolis, IN, USA

Raffaele Califano
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK

Angelo M Carella
Department of Hematology and Stem Cell Transplant Unit, Fondazione IRCCS 'Casa Sollievo della Sofferenza', San Giovanni Rotondo, Foggia, Italy

Enric Carreras
Josep Carreras Leukaemia Research Institute, Hospital Clinic/ University of Barcelona Campus, Barcelona, Spain

Dominique Charron
Denis Diderot University of Paris VII; Department of Immunology and Histocompatibility, Saint-Louis Hospital, Paris, France

Bruce Cheson
Lombardi Comprehensive Cancer Center, Washington, DC, USA

Ezra Cohen
University of Chicago Medical Center, Georgetown University, Chicago, IL, USA

Klaus-Michael Debatin
Department of Paediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany

Gerry Dolan
Department of Haematology, University of Nottingham, Queen's Medical Centre, Nottingham, UK

Massimo Dominici
Medical Oncology, University Hospital of Modena, Modena, Italy

Martin J Edelman
Fox Chase Cancer Center, Philadelphia, PA, USA

Dean A Fennell
Thoracic Medical Oncology, Cancer Research UK, University of Leicester, Leicester, UK

Willem E Fibbe
Department of Immuno-haematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands

Ian W Flinn
Sarah Cannon Research Institute, Nashville, TN, USA

Robin Foa
Institute of Hematology, 'La Sapienza' University of Rome, Rome, Italy

Jan Foubert
Erasmushogeschool Brussel, Anderlecht, Belgium

Dawn M Fucillo
Samaritan Regional Cancer Center, Corvallis, OR, USA

Brenda ES Gibson
Department of Haematology/Oncology, Royal Hospital for Sick Children, Glasgow, UK

Michael K Gibson
University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA

Leonard Girmira
Department of Oncology/Pathology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden

Gerald Gitsch
Department of Obstetrics and Gynaecology, University of Freiburg, Medical School, Freiburg, Germany

Agnes Glaus
Tumour and Breast Centre ZeTUP, St Gallen, Switzerland

Eliane Gluckman
Department of Hematology and Oncology, Saint-Louis Hospital, Paris, France

Vincent Grégoire
Université Catholique de Louvain and Saint-Luc University Hospital, Brussels, Belgium

Axel Grothje
West Cancer Center, Germantown, TN, USA

Louis B Harrison
H Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA

Maureane Hoffman
Duke University Medical Center, Durham, NC, USA

Jørn Herrstedt
Department of Oncology, Odense University Hospital, Odense, Denmark

Maha Hussain
University of Michigan, Ann Arbor, MI, USA

Martin Hutchings
Department of Hematology, The Finsen Centre, National Hospital, Copenhagen University Hospital, Copenhagen, Denmark

Claudine Isaacs
Lombardi Comprehensive Cancer Center, Georgetown University, Chicago, IL, USA

Shai Izraeli
Tel Aviv University; Pediatric Research Institute, Safra Children Hospital, Sheba Medical Center, Tel Hashomer, Israel

Elias Jabbour
University of Texas MD Anderson Cancer Center, Houston, TX, USA

Stefan Karlsson
University of Lund, Lund, Sweden

Daniel Kelly
Royal College of Nursing, School of Healthcare Sciences, Cardiff University, Cardiff, UK

Gary M Kupfer
Yale University School of Medicine, New Haven, CT, USA

Yuer-Hur Lai
School of Nursing, College of Medicine, National Taiwan University, Taipei, Taiwan

Bernhard Lämmle
Center for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany

Per Ljungman
Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden

Steven R Lentz
University of Iowa, Iowa City, IA, USA

Charles D Lopez
Oregon Health & Science University, Portland, OR, USA

Bob Löwenberg
Department of Hematology, Erasmus University Medical Centre, Rotterdam, Netherlands

Mario Mandalà
Department of Oncology and Haematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy

Pier Mannuccio Mannucci
Department of Medicine and Medical Specialties, Maggiore University Hospital of Milan; Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, Milan, Italy

Guido Marcucci
The Ohio State University, Columbus, OH, USA

John L Marshall
Ruesch Center for the Cure of Gastrointestinal Cancers; Lombardi Comprehensive Cancer Center, Washington, DC, USA

Sebastiano Mercadante
Pain Relief and Palliative Care Unit, La Maddalena Cancer Centre, Palermo, Italy

Bruce Minsky
University of Texas MD Anderson Cancer Center, Houston, TX, USA

Constantine S Mitsiades
Harvard Medical School, Boston, MA, USA

Mohamad Mohty
Hematology and Cellular Therapy Department, Saint-Antoine Hospital; University Pierre & Marie C, Paris, France

Michael J Morris
Memorial Sloan Kettering Cancer Center, New York, NY, USA

Judd W Moul
Duke Cancer Center, Durham, NC, USA

David G Mutch
Washington University School of Medicine, St Louis, MO, USA

Arthur Sun Myint
The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral; University of Liverpool, Liverpool, UK

Luigi D Notarangelo
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA

touchREVIEWS

in Oncology & Haematology

Editorial Board

Timothy M Pawlik

Ohio State University College of Medicine, Columbus, OH, USA

Inga Peters

Department of Urology and Urological Oncology, Hannover Medical School, Hannover, Germany

Rob Pieters

Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands

Suresh Ramalingam

Emory University School of Medicine, Atlanta, GA, USA

Bernardo Rapoport

The Medical Oncology Centre of Rosebank, Johannesburg, South Africa

Richard B Reiling

Wright State University, Dayton, OH, USA

Ulrik Ringborg

Cancer Center Karolinska, Karolinska University Hospital, Stockholm, Sweden

Fausto Roila

Medical Oncology Division, Santa Maria della Misericordia Hospital, Perugia, Italy

Frits Rosendaal

Leiden University Medical Center, Leiden, Netherlands

Jesús San Miguel

University Hospital of Salamanca, Salamanca, Spain

Ravindra Sarode

UT Southwestern Medical Center, Dallas, TX, USA

Andrew I Schafer

Weill Cornell Medical College, New York, NY, USA

Lena Sharp

Regional Cancer Center, Stockholm, Sweden

Frank A Sinicrope

Mayo Clinic, Rochester, MN, USA

Susan S Smyth

University of Kentucky, Lexington, KY, USA

Gerard Socié

Department of Bone Marrow Transplantation, Hospital Saint-Louis, Paris, France

Cora Sternberg

Weill Cornell Medicine, New York, NY, USA

Roger Stupp

Malnati Brain Tumor Institute of the Lurie Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Lillian Sung

University of Toronto, Toronto, Ontario, Canada

Ayalew Tefferi

Mayo Clinic, Rochester, MN, USA

Rajeshwar Rao Tekmal

University of Texas Health Science Center, Houston, TX, USA

Swee Lay Thein

Sickle Cell Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA

Ulka Vaishampayan

Wayne State University, Detroit, MI, USA

Catherine Verfaillie

Stem Cell Institute, Catholic University of Leuven, Leuven, Belgium; Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, Minneapolis, MN, USA

Kala Visvanathan

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

Anders Waage

Department of Haematology, St Olavs Hospital and Norwegian University of Science and Technology, Trondheim, Norway

Ulrich Wedding

Department of Palliative Care, Jena University Hospital, Jena, Germany

Antoinette J Wozniak

Wayne State University; Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA

David G Zaridze

Research Institute of Carcinogenesis, Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia

touchREVIEWS

in Oncology & Haematology

Established: January 2005 Frequency: Bi-annual
Current edition: Volume 17 Issue 2, 2021

Aims and Scope

- *touchREVIEWS in Oncology & Haematology* enables time-pressured physicians to stay abreast of major advances and opinion in oncology and haematology practice.
- *touchREVIEWS in Oncology & Haematology* comprises balanced and comprehensive articles written by leading authorities, addressing the most important and salient developments in the oncology and haematology fields.
- *touchREVIEWS in Oncology & Haematology* endeavours to support physicians, clinicians and related healthcare professionals in continuously developing their knowledge, effectiveness and productivity. The editorial policy has been designed to encourage discussion among this peer group.
- Comprehensive bibliographies for each article mean that *touchREVIEWS in Oncology & Haematology* is an informative and valuable reference tool for use throughout the year.
- All articles are subject to peer review, and must adhere to the ICJME, GPP-3, and COPE guidelines.

Structure and Format

- *touchREVIEWS in Oncology & Haematology* is a peer-reviewed, free-to-access, bi-annual journal comprising review articles, case reports, editorials, special reports and original research.
- The structure of each edition of the publication comprises section categories determined by the Editor. The degree of coverage assigned to each category is the decision of the Editor, and in part reflects the views of the Editorial Board.
- All articles declare any author disclosures along with any funding, financial support and medical writing assistance.
- Each edition of *touchREVIEWS in Oncology & Haematology* is published in full online at www.touchONCOLOGY.com

Editorial Expertise

touchREVIEWS in Oncology & Haematology is supported by various levels of expertise:

- Guidance from an Editorial Board consisting of leading authorities from a variety of oncology and haematology disciplines.
- Invited contributors who are recognized authorities from their respective fields.
- Peer review – conducted by experts appointed for their experience and knowledge of a specific topic.
- An experienced team of Editors and Technical Editors.

Peer Review

- On submission, all articles are assessed by the Editor to determine their suitability for inclusion and appropriateness for peer review.
- The Editor identifies appropriate reviewers, who are selected on the basis of their specialist knowledge in the relevant area, following consultation with a member of the Editorial Board where necessary.
- We aim to have the final peer review decision within 4 weeks.

- Following review, papers are either accepted without modification, returned to the author(s) to incorporate required changes, or not accepted for publication.
- The Editor reserves the right to accept or reject any proposed amendments on the advice of the Editorial Board and reviewers.

Submissions and Instructions for Authors

- The Editor commissions articles with guidance from the Editorial Board and unsolicited articles are welcomed.
- The Editor is always keen to hear from authors wishing to discuss potential submissions, and will give due consideration to any proposals. Please contact the Editor for further details.
- 'Instructions for Authors' is available from www.touchONCOLOGY.com

Distribution and Readership

touchREVIEWS in Oncology & Haematology is distributed bi-annually through controlled circulation to senior professionals in the field globally.

Abstracting and Indexing

touchREVIEWS in Oncology & Haematology is abstracted, indexed, and listed in Genamics JournalSeek, Google Scholar, IndexCopernicus and Summon by Serial Solutions.

Copyright

Authors transfer the copyright of the article to Touch Medical Media, who publish the article as free-to-access to registered users.

Online

www.touchmedicalmedia.com provides clinicians and other industry professionals with a free resource of articles from over nine titles, spanning seven therapy areas including cardiology, endocrinology, immunology, neurology, oncology and haematology, ophthalmology and respiratory and pulmonary medicine.

Society Partners

touchONCOLOGY has developed very valuable partnerships with the most respected not-for-profit medical societies both in Europe and the USA. These partnerships are key as touchONCOLOGY.com helps to promote awareness of these medical societies whilst also providing free-to-access, peer reviewed articles and multimedia content to the society members, which ensures that the industry is kept up-to-date with the latest cutting-edge content and opinion from world-renowned doctors.

About Touch Medical Media

Touch Medical Media publishes a rich and diverse portfolio of free-to-access, peer-reviewed journals across the clinical and pharmaceutical arenas. Touch Medical Media aims to assist in the education and practice of healthcare and pharmaceutical professionals. □




A personalized approach to treating thyroid cancer: Biomarker testing and the promise of targeted therapies



CONTINUALLY IMPROVING CARE:

Evolving role of the MDT in early *EGFR*-mutant NSCLC





Foreword

55 Foreword

Shaji K Kumar¹ and Axel S Merseburger²

1. Mayo Clinic, Rochester, MN, USA; 2. Department of Urology, Campus Lübeck, University Hospital Schleswig-Holstein, Lübeck, Germany

Expert Interview

Prostate Cancer

56 The Future of Advanced Prostate Cancer Treatment

An Expert Interview with Axel S Merseburger

Department of Urology, University of Lübeck, Lübeck, Germany

Editorial

Dermatological Cancer

58 Lymphocyte-activation Gene 3 and Programmed Cell Death 1 Checkpoint Inhibition as a Novel Combination in Advanced Melanoma

Michael Serzan¹⁻³ and Michael B Atkins¹⁻³

1. Lombardi Comprehensive Cancer Center, Washington, DC, USA; 2. Georgetown University Medical Center, Washington, DC, USA; 3. MedStar Georgetown University Hospital, Washington, DC, USA

Reviews

Breast Cancer

60 A New Standard of Care: Pembrolizumab in Programmed Death-ligand 1 Positive, Metastatic, Triple-negative Breast Cancer

Kai CC Johnson,¹ Robert Wesolowski^{1,2} and Margaret E Gatti-Mays^{1,2}

1. Stefanie Spielman Comprehensive Breast Center, Columbus, OH, USA; 2. Pelotonia Institute for Immunology, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA

Gynaecological Oncology

68 Tisotumab Vedotin in Cervical Cancer: Current Status and Future Perspectives

Elena Giudice,¹ Floriana Camarda,² Vanda Salutari,³ Caterina Ricci,³ Camilla Nero,³ Maria Vittoria Carbone,³ Viola Ghizzoni,¹ Lucia Musacchio,³ Chiara Landolfo,³ Maria Teresa Perri,¹ Giovanni Scambia^{1,3} and Domenica Lorusso^{1,3}


1. Institute of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; 2. Oncologia Medica, Comprehensive Cancer Center, Università Cattolica del Sacro Cuore, Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy; 3. Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

Haematological Malignancies

73 Bruton's Tyrosine Kinase Inhibitors for the Treatment of Waldenström's Macroglobulinaemia: A Canadian Perspective

Frederic Larose and Christine I Chen

Princess Margaret Cancer Centre, Toronto, Canada



Reviews

Haematological Malignancies

- 79 Daratumumab for Immunoglobulin Light Chain Amyloidosis**
Foteini Theodorakakou, Meletios A Dimopoulos and Efstathios Kastritis
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

- 84 Pegcetacoplan in Paroxysmal Nocturnal Haemoglobinuria**
Richard J Kelly, Alexandra Pike, Daniel Payne and Morag Griffin
Department of Haematology, St James's University Hospital, Leeds, UK

Immunotherapy

- 90 New Checkpoint Inhibitors and Immunotherapies for Solid Tumours**
Inderjit Mehmi, Kristopher P Wentzel and Omid Hamid
The Angeles Clinic and Research Institute, A Cedar-Sinai Affiliate, Los Angeles, CA, USA

Lymphoma

- 95 The Anti-CD19 Antibody–Drug Conjugate Loncastuximab Tesirine**
Krishna Goparaju,¹ Allison Winter^{2,3} and Paolo F Caimi^{2,3}
1. Department of Medicine, Division of Hematology and Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; 2. Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH, USA; 3. Case Comprehensive Cancer Center, Cleveland, OH, USA

Multiple Myeloma

- 101 Melphalan Flufenamide: a Peptide–Drug Conjugate for the Treatment of Multiple Myeloma**
Dickran Kazandjian and Ola Landgren
Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA

Prostate Cancer

- 107 New and Emerging Therapeutics for Non-metastatic Castrate-resistant Prostate Cancer**
Ryan B Sinit¹ and Julie N Graff^{1,2}
Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA; 2. VA Portland Health Care System, Portland, OR, USA

Case Report

Lymphoma

- 111 Haplo-identical Haematopoietic Stem Cell Transplantation in Refractory Hodgkin Lymphoma After Carmustine, Etoposide, Cytarabine, Melphalan Conditioning Regimen**
Nour B Abdeljelil,^{1,2} Dorra Belloumi,^{1,2} Sabrine Mekni,^{1,2} Amel Lakhal,^{1,2} Lamia Torjeman,^{1,2} Saloua Ladeb,^{1,2} Tarek B Othman^{1,2}
1. Department of Haematology, National Bone Marrow Transplantation Centre of Tunis, Tunis, Tunisia; 2. Faculté de Médecine de Tunis, Université de Tunis El Manar, Tunis, Tunisia